Protein Summary
Part of an E3 ubiquitin ligase complex for neddylation. Promotes neddylation of cullin components of E3 cullin-RING ubiquitin ligase complexes. Acts by binding to cullin-RBX1 complexes in the cytoplasm and promoting their nuclear translocation, enhancing recruitment of E2-NEDD8 (UBE2M-NEDD8) thioester to the complex, and optimizing the orientation of proteins in the complex to allow efficient transfer of NEDD8 from the E2 to the cullin substrates. Involved in the release of inhibitory effets of CAND1 on cullin-RING ligase E3 complex assembly and activity (PubMed:25349211, PubMed:28581483). Acts also as an oncogene facilitating malignant transformation and carcinogenic progression (By similarity).
- ENST00000292782
- ENSP00000292782
- ENSG00000043093
- DCN1
- DCUN1L1
- RP42
- SCCRO
- RP42
- SCRO
- Tes3
- DCNL1
- SCCRO
- DCUN1L1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.88 | ||
histone modification site profile | 0.81 | ||
kinase perturbation | 0.66 | ||
tissue sample | 0.66 | ||
cell line | 0.56 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.02 (req: < 5)
Gene RIFs: 16 (req: <= 3)
Antibodies: 258 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 48.02 (req: >= 5)
Gene RIFs: 16 (req: > 3)
Antibodies: 258 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 116
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0